← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue decreased 51.2% to $6.6M, while Net income increased 26.8% to ($136.3M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $6.6MWatch
- Profitability — Net income ($136.3M)Watch
- Cash generation — Free cash flow ($112.0M)Note
- Accounting — Formula distress score · no manipulation flag · earnings quality greyWatch
- Insiders — 0 buys; 2 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
FATE THERAPEUTICS INC: Development of our product candidates will require substantial additional funding, which, if available, may cause dilution to our stockholders, and without which we will be unable to complete preclinical or clinical development of, or obtain regulatory approval for, our product candidates.
Where the revenue comes from
Fiscal 2024, as FATE THERAPEUTICS INC reports it. History and quarterly detail are in the app.
Leadership changes
From FATE THERAPEUTICS INC's own filings, the day they're filed.
- Neelufar Mozaffarian · Directors · departureeff. 2025-10-13
- Bahram Valamehr · director · appointmenteff. 2025-01-01
- Subsidiary Roles · President · departureeff. 2025-01-01
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-06-15
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about FATE THERAPEUTICS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.